TABLE 3.

Summary of descriptive statistics of ABX464 PK parameters after the first and fourth single oral administration of 50 mg ABX464 (day 1 and day 10) under fasted and fed conditions to group 2 subjects^a

Condition and/or value	Day 1				Day 10
	Cmax (ng/ml)	Tmaxb (h)	AUC0–t (ng · h/ml)	t1/2 (h)	Cmax (ng/ml)	Tmaxb (h)	AUC0–t (ng · h/ml)	t1/2 (h)
Fasted	n = 12	n = 12	n = 12	n = 4	n = 12	n = 12	n = 12	n = 9
Mean	11.19	1.75	31.49	1.11	10.75	1.8	28.26	1.15
SD	4.98	1.00–2.50	18.28	0.68	4.63	1.0–3.0	14.82	0.52
GM	10.00		26.92	0.99	9.93		25.16	1.08
Fed	n = 12	n = 12	n = 12	n = 6	n = 12	n = 12	n = 12	n = 8
Mean	46.67	2.50	112.66	0.77	55.38	2.3	111.24	0.74
SD	16.45	2.00–4.00	39.52	0.14	43.04	1.5–4.0	72.43	0.15
GM	42.92		105.22	0.76	42.79		93.19	0.73
Point estimate	4.29		3.91		4.31		3.70
90% CI	3.03–6.08		2.74–5.58		2.82–6.59		2.51–5.47

^aC_max, maximum concentration; T_max, time to maximum concentration; AUC_0–t, area under the concentration-time curve from time zero to the time of last quantifiable concentration; AUC_0–∞, AUC from time zero to infinity; t_1/2, apparent terminal elimination half-life; n, number of subjects; SD, standard deviation; GM, geometric mean; CI, confidence interval.

^bInstead of means and standard deviations, the values given for this parameter are medians and ranges (minimum–maximum), respectively.